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Marking the Fine Line: Ethics and the 
Regulation of Innovative Technologies in 
Human Reproduction 
Anne Drapkin Lyerly*
I don’t remember Mr. Steptoe saying his method of producing babies 
had ever worked, and I certainly didn’t ask. I just imagined that 
hundreds of children had already been born through being conceived 
outside their mothers’ wombs. 
 
Lesley and John Brown1
I. INTRODUCTION 
 
On July 25, 1978 in England, Louise Brown became the 
first baby born by in vitro fertilization (IVF).2 Three years 
later, Elizabeth Carr followed suit as the first “test tube baby” 
born in the United States.3 Since then, much has changed in 
the field of human reproduction. Once reported “with a fervor 
not seen since the first moon landing,”4 the birth of a child from 
IVF now accounts for more than one in sixty births in the UK, 5
                                                          
 2010 Anne Drapkin Lyerly. 
 
* Anne Drapkin Lyerly, M.D., M.A., is an Associate Professor of Obstetrics and 
Gynecology at Duke University School of Medicine. The framework for this 
paper is based in large part on research and conversations during her tenure 
as a Greenwall Fellow on the staff on the National Bioethics Advisory 
Commission (NBAC). She is particularly indebted to Eric Meslin and Elisa 
Gordon for their input in this regard, and to Ruth Faden and the Greenwall 
Foundation for making her experience on NBAC possible. Her recent work on 
this topic has been supported by a career development award from the 
National Institutes of Health, 5 K01 HL072437-05. 
 1. LESLEY BROWN & JOHN BROWN WITH SUE FREEMAN, OUR MIRACLE 
CALLED LOUISE: A PARENT’S STORY 106 (Padington Press 1979). 
 2. LORI B. ANDREWS, THE CLONE AGE: ADVENTURES IN THE NEW WORLD 
OF REPRODUCTIVE TECHNOLOGY 15 (1999). 
 3. Id. at 31. 
 4. Id. at 15. 
 5. Human Fertilisation & Embryology Authority, Latest UK IVF 
Figures–2007 (Sept. 30, 2009), http://www.hfea.gov.uk/ivf-figures-
2006.html#1279 (last visited Apr. 22, 2010) (noting that “[a]round 1.5% of all 
births and 1.8% of all babies born in the UK are the result of IVF and donor 
686 MINN. J. L. SCI. & TECH. [Vol. 11:2 
 
 
approximately one in eighty babies in the United States,6 and 
assisted reproductive technologies (ARTs) constitute a 
burgeoning medical practice worldwide. More than three 
million children have been created by IVF;7 the United States 
alone can boast of more than 41,300 births per year resulting in 
54,600 babies per year (due to twins, triplets, and higher order 
multiple gestations)8 and generating an annual revenue of 
nearly 3 billion dollars.9
Indications for ARTs and the level of technological and 
scientific sophistication have expanded as well. Originally 
developed as a means to overcome infertility resulting from 
damaged fallopian tubes, ARTs are now used to address other 
sources of infertility, such as ovulation problems and 
endometriosis in women, poor sperm quality or function in 
men, and unexplained causes of failed conception.
 
10
With the highly publicized scandals associated with the 
fertility industry, calls for more regulation of ARTs in the 
 The ability 
to fertilize and manipulate embryos outside the womb has also 
led to the development of techniques to screen for genetic 
disease and selectively implant only “healthy” embryos. In the 
midst of the rapid evolution of ARTs, however, one aspect of the 
field has remained remarkably constant in the United States: 
there has been virtually no effective regulatory protection for 
the human subjects who participate in or who are affected by 
the process of innovating new techniques in reproductive 
medicine. 
                                                          
insemination”). 
 6. See CTRS. FOR DISEASE CONTROL & PREVENTION, DEP’T OF HEALTH & 
HUMAN SERVS., NATIONAL VITAL STATISTICS REPORTS, Jan. 7, 2009, at 1, 
available at http://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57_07.pdf 
[hereinafter FINAL DATA FOR 2006] (stating that “[a] total of 4,265,555 births 
were registered in the United States in 2006); CTRS. FOR DISEASE CONTROL & 
PREVENTION ET AL., DEP’T OF HEALTH & HUMAN SERVS., 2006 ASSISTED 
REPRODUCTIVE TECHNOLOGY SUCCESS RATES 61 (2008), available at 
http://www.cdc.gov/art/ART2006/508PDF/2006ART.pdf [hereinafter 2006 
ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS RATES] (stating that in 2006 
54,656 infants were born that were conceived using ART procedures). 
 7. Zev Rosenwaks & Kristin Bendikson, Commentary, Further Evidence 
of the Safety of Assisted Reproductive Technologies, 104 PROC. NAT’L ACAD. 
SCI. 5709, 5709 (2007), available at 
http://www.pnas.org/content/104/14/5709.full.pdf+html. 
 8. 2006 ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS RATES, supra 
note 6, at 61. 
 9. DEBORA L. SPAR, THE BABY BUSINESS: HOW MONEY, SCIENCE, AND 
POLITICS DRIVE THE COMMERCE OF CONCEPTION 32–33 (2006). 
 10. Id. at 1–2. 
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United States have been frequent and emphatic. Indeed, the 
birth of octuplets last year inspired vigorous debate about the 
adequacy and role of professional guidelines as arbiters of 
appropriate and safe care.11 Yet, the best of the dialogue—
especially of late—has focused primarily on regulation of 
practice.  
For example, such debates focus on how we ought to regulate 
the exchange of gametes;12 whether there should be stricter 
limits on how many embryos can be transferred to a woman’s 
uterus during a single cycle; whether the informed consent 
process should be standardized; whether insurance coverage for 
fertility treatment ought to be mandated;13
This paper aims to pry apart and highlight the particular 
issue of innovation in reproductive medicine as distinct from 
other areas of controversy in regulating this field, and one for 
which the case for regulation is particularly strong. It begins 
with a description of a clinical case that exemplifies the nature 
of and problems associated with the lack of regulatory 
oversight. Next, follows a description of factors that have 
contributed to the current state of affairs. The paper then 
articulates three reasons why better oversight for innovation is 
ethically necessary, and concludes with four opportunities for 
potential progress. 
 whether access to 
ARTs can be ethically restricted based on age, health, sexual 
orientation. These are all important questions, indeed. But far 
less attention has been directed at the regulation of research—
of oversight for the process of moving from bench to bedside, 
innovation to practice. If we are concerned about the safe and 
ethical provision of reproductive medicine in the 21st century, 
the role of regulation of this process is a topic that deserves, at 
the very least, our equal attention. 
II. UNREGULATED INNOVATION: A CLINICAL EXAMPLE 
Perhaps well known by now is a clinical case that 
                                                          
 11. See, e.g., Howard Minkoff & Jeffrey Ecker, The California Octuplets 
and the Duties of Reproductive Endocrinologists, 201 AM. J. OBSTETRICS & 
GYNECOLOGY 15.e1, 15.e1 (2009); John A. Robertson, The Octuplet Case—Why 
More Regulation is Not Likely, 39 HASTINGS CENTER REP., May 2009, at 26, 
27. 
 12. See NAOMI R. CAHN, TEST TUBE FAMILIES: WHY THE FERTILITY 
MARKET NEEDS LEGAL REGULATION 146 (2009). 
 13. See Naomi R. Cahn & Jennifer M. Collins, Eight is Enough, 103 NW. 
U. L. REV. 501, 503–04 (2009), available at 
http://www.law.northwestern.edu/lawreview/colloquy/2009/22/LRColl2009n22
Cahn&Collins.pdf. 
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exemplifies the lack of regulation of innovation in reproductive 
medicine and reasons for concern. In 1992, a new technique to 
achieve fertilization known as ICSI (intracytoplasmic sperm 
injection) was introduced in Belgium as a treatment for male 
factor infertility.14 The technique involves the injection of a 
single sperm into an egg to achieve fertilization (as opposed to 
standard IVF, in which sperm and eggs are mixed together, 
allowing fertilization to occur spontaneously).15 Within a year 
of the first reported ICSI pregnancy in Belgium, the technique 
was introduced in the United States and quickly became widely 
utilized by many programs.16 By 1997, an average of 30% of 
U.S. ART cycles used ICSI,17 with some centers using the 
technique in as many as 73% of all cycles. 18 By 2006, the 
percent of fresh cycles using ICSI cycles had climbed to 62% 
overall.19 Equally striking is the fact that this dramatic rise in 
ICSI curiously occurred while the proportion of patients 
receiving treatment for male-factor infertility remained 
stable.20
Amidst the enthusiasm regarding this innovative 
technology, concerns about safety surfaced. No experimental 
phase preceded its introduction, in part due to absence of an 
adequate experimental model,
 
21 and in part due to “its 
immediate and overwhelming success.”22
                                                          
 14. Gianpiero Palermo et al., Pregnancies After Intracytoplasmic Injection 
of Single Spermatozoon into an Oocyte, 340 LANCET 17, 17–18 (1992). 
 But as children 
conceived by ICSI were evaluated in Europe, data regarding 
short and long-term outcomes suggested that some may be at 
 15. Gina Kolata, New Pregnancy Hope: A Single Sperm, N.Y. TIMES, Aug. 
11, 1993, at C11. 
 16. Id. 
 17. CTRS. FOR DISEASE CONTROL & PREVENTION ET AL., DEP’T OF HEALTH 
& HUMAN SERVS., 1997 ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS 
RATES 25 (1999), available at 
http://www.cdc.gov/art/ArchivedARTPDFs/97art.pdf [hereinafter 1997 
ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS RATES]. 
 18. Id. at 127 (citing the Fertility Institute of Northwest Florida). 
 19. 2006 ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS RATES, supra 
note 6, at 39. 
 20. See Tarun Jain & Ruchi S. Gupta, Trends in the Use of 
Intracytoplasmic Sperm Injection in the United States, 357 NEW ENG. J. MED. 
251, 251 (2007). 
 21. See R. Yanagimachi, Is an Animal Model Needed for Intracytoplasmic 
Sperm Injection (ICSI) and Other Assisted Reproduction Technologies?, 10 
HUM. REPROD. 2525, 2526 (1995). 
 22. E. R. te Velde et al., Commentary, Concerns About Assisted 
Reproduction, 351 LANCET 1524, 1524 (1998). 
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increased risk for health problems. Some studies suggested an 
increased risk of abnormalities in sex23 and autosomal 
chromosomes.24 Follow-up of developmental parameters in 
children conceived by ICSI also suggested that there may be an 
increased risk of mild developmental delay.25 Other studies 
demonstrated a scientific basis for the possibility of an 
increased risk of neurodegenerative disease26 and malignancy 
later in life27
Even if short and long term data eventually allay some of 
the safety concerns about ICSI (as some recently have, 
including a report demonstrating the absence of alterations in 
DNA point mutations in IVF embryos
 in children conceived by ICSI, and long-term 
consequences of the procedure remain unknown. In the absence 
of regulation regarding the introduction of this new ART, tens 
of thousands of children have been created by a technology of 
unproven safety. 
28), scores of concerns 
about the safety of fertility treatment in general remain. Such 
concerns are derived, at least in part, from the paucity of 
oversight that has governed the translation of ARTs into 
practice. Most recently, concerns have been broadly publicized 
about the impact of IVF on a process called “imprinting,” which 
involves changes in the pattern of gene expression. The 
concerns grew out of reports of an apparent increased 
frequency in rare genetic disorders in children conceived 
through both IVF and ICSI,29
                                                          
 23. See Peter In’t Veld et al., Sex Chromosomal Abnormalities and 
Intracytoplasmic Sperm Injection, 346 LANCET 773, 773 (1995). 
 possibly attributable to the type 
of medium in which in vitro embryos are grown before they are 
placed in a woman’s body. Other data indicate an increased 
risk of heart defects, cleft lip, esophageal and anorectal atresia 
in infants conceived with ART, though the mechanisms behind 
 24. See André Van Steirteghem et al., Is ICSI the Ultimate ART 
Procedure?, in INTERNATIONAL CONGRESS SERIES 1183, FERTILITY AND 
REPRODUCTIVE MEDICINE, 27, 33 (Roger D.Kempers et al. eds., 1998). 
 25. See Jennifer R. Bowen et al., Medical and Developmental Outcome at 1 
Year for Children Conceived by Intracytoplasmic Sperm Injection, 351 LANCET 
1529, 1532 (1998). 
 26. See Aneta T. Dowsing et al., Linkage Between Male Infertility and 
Trinucleotide Repeat Expansion in the Androgen-Receptor Gene, 354 LANCET 
640, 640 (1999). 
 27. David Nudell et al., Increased Frequency of Mutations in DNA from 
Infertile Men with Meiotic Arrest, 15 HUM. REPROD. 1289, 1293 (2000) (noting 
a possible increase in risk of “somatic defects later in life”). 
 28. Rosenwaks & Bendikson, supra note 7, at 5709. 
 29. See Somjate Manipalviratn et al., Imprinting Disorders and Assisted 
Reproductive Technology, 91 FERTILITY & STERILITY 305, 313–314 (2009). 
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such trends remain uncertain.30 Amidst efforts to reassure 
patients and the public, a growing consensus points to risks for 
offspring, and responsibility to identify and minimize them.31
Less attention has been directed at the equally concerning 
paucity of data on the implications of ARTs for the health and 
well-being of women whose bodies (and lives) interface with 
novel techniques. A 2008 Cochrane review of outcomes of 
interventions used in the treatment of infertility indicated that 
most randomized studies conducted since 2000 either did not 
measure the short or long term health impact of fertility 
treatment on women, or did not have sufficient power to detect 
meaningful differences in delivery rates or obstetric outcomes, 
particularly less frequent outcomes such as complications 
affecting maternal health.
 
32 Data regarding ARTs and breast 
and ovarian cancer are reassuring, but insufficient to rule out 
increased risk with treatment. Data on other health 
parameters indicate reason for worry. In particular, a higher 
likelihood of abnormal placentation disorders in women 
pregnant from IVF (pre-eclampsia, placenta previa, and 
placental abruption)33
III. REASONS FOR THE LACK OF OVERSIGHT 
 is not only immediately threatening to 
maternal health, but may be a harbinger of cardiovascular risk 
in mothers in the longer term. Despite the widespread use of 
ARTs, research on the long term impact of women’s health 
treatment is scarce. 
As the above suggests, innovation in human reproduction 
in the United States has not advanced under the regulatory 
oversight applied to other areas of research on human subjects. 
At least two forces at play help to explain why. First, an array 
of cultural, scientific, political and economic forces has served 
to dissociate reproductive medicine—innovative or otherwise—
                                                          
 30. J. Reefhuis et al., Assisted Reproductive Technology and Major 
Structural Birth Defects in the United States, 24 HUM. REPROD. 360, 360 
(2009). 
 31. See Gina Kolata, Picture Emerging on Genetic Risks of IVF, N.Y. 
TIMES, Feb. 17, 2009, at D1 [hereinafter Picture Emerging on Genetic Risks of 
IVF]. 
 32. AGENCY FOR HEALTHCARE RESEARCH & QUALITY, DEP’T OF HEALTH & 
HUMAN SERVS., EFFECTIVENESS OF ASSISTED REPRODUCTIVE TECHNOLOGY v 
(2008), available at 
http://www.ahrq.gov/downloads/pub/evidence/pdf/infertility/infertility.pdf 
[hereinafter EFFECTIVENESS OF ASSISTED REPRODUCTIVE TECHNOLOGY]. 
 33. Id. at 111. 
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from its connotations as a research endeavor. Second, even for 
innovations that all would agree fall within the definition of 
research, traditional sources of regulatory control have not 
been applied. 
A. RESEARCH AND PRACTICE 
Reproductive medicine has come to occupy a unique locus 
on the spectrum of research and practice, largely as a result of 
the cultural, scientific, political, and economic contexts in 
which it has evolved. As Robert Blank observed more than a 
decade ago, the application of new technology has been 
generally dissociated from the term “experimentation,” raising 
concern “about whether participants are patients, subjects, or 
both.”34
1. Cultural Backdrop 
 As a result, constraints which usually apply to other 
fields of medicine are not applied to reproductive medicine, and 
innovation in the field proceeds without protection of 
individuals who engage (as patients or participants) in novel 
reproductive interventions. Some of the forces that have 
worked to dissociate “innovation” from “research” or 
“experimentation” are discussed below. 
First, innovation in reproductive medicine has taken place 
against a cultural backdrop of protectionist policies toward 
women of childbearing potential, pregnant women, and fetuses. 
As described in the IOM report on Women and Health 
Research, two events in the 1960s and early 1970s “amplif[ied] 
public sentiment about the need for greater protection for 
fetuses from risks in science and medicine.”35 The discovery 
that thalidomide, a drug approved in twenty countries outside 
the United States for nausea in early pregnancy caused severe 
limb deformities in children powerfully fostered aversion to 
involving pregnant women and women of childbearing age in 
drug research.36
                                                          
 34. Robert H. Blank, Assisted Reproduction and Reproductive Rights: The 
Case of In Vitro Fertilization, 16 POL. & LIFE SCI. 279, 283 (1997). 
 The other event, the discovery that 
diethylstilbestrol (DES) caused a number of abnormalities of 
the genital tract in daughters of women who took the drug to 
prevent miscarriage, served to strengthen public sentiment 
 35. 1 COMM. ON THE ETHICAL AND LEGAL ISSUES RELATING TO THE 
INCLUSION OF WOMEN, INST. OF MED., WOMEN AND HEALTH RESEARCH: 
ETHICAL AND LEGAL ISSUES OF INCLUDING WOMEN IN CLINICAL STUDIES 40 
(Anna C. Mastroianni et al. eds., 1994). 
 36. Id. 
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opposing pharmaceutical innovation in women who were 
pregnant or of childbearing potential.37 The FDA issued 
guidelines in 1977 that recommended exclusion of women of 
childbearing potential from early phases of drug trials.38
Although these events occurred in the setting of trials of 
drugs rather than the introduction of devices or procedures, the 
results of the exclusionary policy tell an important story about 
the consequences of “protection” from experimentation in 
general. Consider their impact on the knowledge base about 
post-conception reproductive medicine. The idea that women 
and fetuses can and should be protected from research, rather 
than through research has resulted in a profound dearth of 
information about the safety and appropriate use of 
medications during pregnancy.
 
39 Approximately two thirds of 
women are prescribed at least one medication other than a 
vitamin or mineral supplement during pregnancy.40 Yet the 
evidence base for determining how and whether to dose such 
medications or treat illness during pregnancy is distressingly 
poor. Only a dozen medications are approved for use by the 
FDA during pregnancy and all are for gestation or birth related 
issues such as anesthesia or nausea.41 Any medicine used to 
treat illness during pregnancy is prescribed without adequate 
data on dosing or safety. Paradoxically, protectionist policies 
have thrust innovation in drug therapy for pregnant women 
out of the protective umbrella of pharmaceutical regulation into 
the predominantly unregulated realm of off-label use.42
                                                          
 37. Id. at 41. 
 
 38. See FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH, EDUC., & WELFARE, 
GENERAL CONSIDERATION FOR THE CLINICAL EVALUATION OF DRUGS 15–16 
(1977). 
 39. See Anne Drapkin Lyerly et al., Pregnancy and Clinical Research, 
HASTINGS CENTER REP., Nov. – Dec. 2008, at 53, 53 [hereinafter Pregnancy 
and Clinical Research] (stating that “[I]f we are to treat pregnant women’s 
illnesses effectively—something crucial to the health of both pregnant women 
and the children they bear—we must study medications in pregnant women.”) 
(emphasis in original). 
 40. See Susan E. Andrade et al., Prescription Drug Use in Pregnancy, 191 
AM. J. OBSTETRICS & GYNECOLOGY 398, 400 (2004) (finding that for 64% of 
deliveries in the study, “a drug other than a vitamin or mineral supplement 
was dispensed in the 270 days before delivery”). 
 41. Doris Haire, Nat’l Women’s Health Alliance, FDA Approved Obstetrics 
Drugs: Their Effects on Mother and Baby, 
http://www.nwhalliance.org/FDAAPPROVED.htm (last visited Apr. 22, 2010) 
(providing a list and description of drugs approved for use by the FDA during 
pregnancy). 
 42. See Anne Drapkin Lyerly et al., The Second Wave: Toward 
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A related set of cultural factors has led to a dearth of 
research pertaining to the health of women who participate in 
ARTs: tendencies to overlook the gestating (or in the case of 
ARTs, potentially gestating) woman as a patient, subject, or 
research participant in her own right. Many have pointed out a 
longstanding and pervasive tendency in reproductive health to 
focus primarily or exclusively on risks and benefits to offspring 
to the exclusion of risks and benefits to women themselves.43 
The tendency can be attributed in part to approaches that 
regard the pregnant woman and her fetus as separate, which 
obscure “the physical and social relationship between pregnant 
woman and fetus, the ways that maternal and fetal 
physiologies and welfare are linked, and perhaps . . . the 
woman herself.”44 Indeed, even in cases where innovative 
procedures in post-conception reproductive medicine have been 
recognized as research endeavors, maternal outcomes are often 
not measured. For instance, surgical interventions to correct 
birth defects in-utero have generated a notable paucity of 
studies measuring short and long-term outcomes for women, 
compared to those measuring the impact on children.45 Recent 
efforts to redress the dearth of evidence have identified 
significant risks for women of pre-birth intervention.46 And 
while the best known examples regard post-conception research 
(maternal-fetal surgery or research on AIDS during pregnancy) 
as opposed to ARTs, the tendency to overlook maternal health 
as an end in its own right spans the reproductive medicine from 
pre-conception to years after birth.47
                                                          
Responsible Inclusion of Pregnant Women in Research, INT’L J. FEMINIST 
APPROACHES TO BIOETHICS, Fall 2008, at 5, 7 [hereinafter The Second Wave]. 
 
 43. See Ruth Faden et al., Women as Vessels and Vectors: Lessons From 
the HIV Epidemic, in FEMINISM AND BIOETHICS: BEYOND REPRODUCTION 252, 
253 (Susan M. Wolf ed., 1996). 
 44. Anne Drapkin Lyerly et al., A Critique of the ‘Fetus as Patient’, AM. J. 
BIOETHICS, July 2008, at 42, 43 [hereinafter A Critique of the ‘Fetus as 
Patient’]. 
 45. See Anne Drapkin Lyerly et al., Toward the Ethical Evaluation and 
Use of Maternal-Fetal Surgery, 98 AM. J. OBSTETRICS & GYNECOLOGY 689, 
695–696 (2001) [hereinafter Toward the Ethical Evaluation and Use]. 
 46. Kristin Golombeck et al., Maternal Morbidity After Maternal-Fetal 
Surgery, 194 AM. J. OBSTETRICS & GYNECOLOGY 834, 838 (2006) (finding that 
“short-term maternal morbidity is related directly to the invasiveness of the 
technique”). 
 47. Anne Drapkin Lyerly et al., Commentary, The National Children’s 
Study: A Golden Opportunity to Advance the Health of Pregnant Women, 99 
AM. J. PUB. HEALTH 1742, 1742 (2009) [hereinafter The National Children’s 
Study]. 
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2. Scientific & Cultural Context 
A second force separating ARTs from connotations of 
research and outside its regulatory protections is their 
scientific and clinical context. A significant proportion of 
innovation in reproductive medicine involves medical 
procedures, which lack the explicit regulatory mechanisms for 
ensuring safety and efficacy that apply to drugs.48 Reproductive 
medicine shares with other procedure-related specialties, such 
as general surgery, an exemption from the strenuous research 
and approval process applied to pharmaceuticals. In his 
testimony to the National Bioethics Advisory Commission 
(NBAC) on July 11, 2000, Dr. Sam Wells, Director of Clinical 
Trials and Evidence Based Medicine for the American College 
of Surgeons noted how surgery has “fallen under the radar 
screen of oversight and surveillance,” since there is “no FDA for 
surgery. . . .”49 As a result, new procedures may be performed 
and integrated into clinical practice without proof of safety, 
efficacy, or superiority to standard therapy.50
Furthering the challenges engendered by its status as a 
surgical specialty, the endpoints assessed in innovative 
procedures in reproductive medicine make assumptions about 
their therapeutic status arguably more likely. For the end 
result of ARTs is measured not in a clinical parameter such as 
blood pressure or cholesterol, cancer-free survival, even quality 
of life, but in the presence or absence of a child. Indeed, as 
Andrea Bonnicksen recently observed, “it appears that ARTs 
are efficacious in that the key outcome, the take-home baby 
rate, has steadily improved for most programs.”
 
51
                                                          
 48. See generally Charles B. Wilson, Adoption of New Surgical 
Technology, 332 BRIT. MED. J. 112 (2006) (arguing that new surgical 
technologies should be subjected to a higher level of scrutiny); see also Steven 
M. Strasberg & Philip A. Ludbrook, Who Oversees Innovative Practice? Is 
There a Structure that Meets the Monitoring Needs of New Techniques?, 196 J. 
AM. C. SURGEONS 938, 946 (2003) (arguing that agency oversight is needed for 
new surgical techniques). 
 Indeed, it 
may unpalatable for many to think of child as the successful 
 49. Samuel A. Wells, Jr., Dir. of Clinical Trials & Evidence-Based Medic., 
Am. Coll. of Surgeons, Statement at a Meeting of the National Bioethics 
Advisory Commission (Jan. 11, 2000), at 226, available at 
http://bioethics.georgetown.edu/nbac/transcripts/july00/7-00day2pt2.pdf. 
 50. Id. 
 51. Andrea L. Bonnicksen, Oversight of Assisted Reproductive 
Technologies: The Last Twenty Years, in REPROGENETICS: LAW, POLICY, AND 
ETHICAL ISSUES 64, 81 (Lori P. Knowles & Gregory E. Kaebnick eds., 2007). 
2010] MARKING THE FINE LINE 695 
product of an experiment. Thus the clinical context in which 
innovation in reproductive medicine takes place further 
implements exceptionalism with respect to regulations and 
protections for individuals exposed to untested interventions. 
3. Politics 
Third, the political context in which new therapies in 
reproductive medicine are implemented has encouraged the 
dissociation of reproductive medicine from connotations of 
research. In the United States, a so-called “failure of political 
nerve,” has powerfully shaped the recalcitrance about 
regulation. 52 In the sphere of innovation, this recalcitrance is 
manifested most forcibly by the consistent failure, in the last 
four decades, by the federal government to provide funding for 
research on human embryos and fetuses. In 2000, the late John 
Fletcher noted “with sadness” that “a whole generation of 
researchers in reproductive medicine has been without federal 
support of fetal research and study of the beginning of 
embryonic development.”53 Despite considerable advocacy for 
advancement of stem cell research, research on early embryos 
has had to progress without the funding—or oversight—of the 
federal government. President George W. Bush authorized 
research funding for a limited number of stem cell lines derived 
from human embryos before August 9, 2001.54 In March 2009, 
President Obama issued an executive order rescinding Bush 
era limits and allowing research on stem cell lines created after 
that date.55
Oversight will be addressed in greater depth in the 
following section; for the purposes of the present discussion, 
though, it is important to note the lack of federal funding as a 
factor leading to the definition of innovation in reproductive 
medicine as something other than research. New technologies 
are introduced into practice without having been scrutinized for 
 Despite these steps forward, it remains the case 
that the federal government has not exerted influence through 
research funding to shape expectations about the appropriate 
translation of innovative ARTs into clinical practice. 
                                                          
 52. Cynthia B. Cohen, Unmanaged Care: The Need to Regulate New 
Reproductive Technologies in the United States, 11 BIOETHICS 348, 357 (1997). 
 53. John C. Fletcher, Deliberating Incrementally on Human Pluripotential 
Stem Cell Research, in NAT’L BIOETHICS ADVISORY COMM’N, ETHICAL ISSUES 
IN HUMAN STEM CELL RESEARCH, VOLUME II, E-1, E-42 (2000). 
 54. See NIH’s Role in Federal Policy [Stem Cell Information], 
http://stemcells.nih.gov/policy/NIHFedPolicy.asp (last visited Apr. 1, 2010). 
 55. Exec. Order No. 13505, 74 Fed. Reg. 10667 (Mar. 9, 2009). 
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safety or efficacy. Independent clinics offering ARTs are not 
required to set up Institutional Review Boards (IRBs), nor are 
their innovative therapies subject to the Department of Health 
and Human Services (DHHS) regulations, which protect 
human subjects who participate in other areas of medical 
innovation. What evolved from the federal policy, Bonnicksen 
has noted, is the ironic fact that new reproductive technologies 




Economic forces have further encouraged the dissociation 
of ARTs and research. The high demand for these innovative 
reproductive services coupled with a void in federal funding 
and oversight has helped to make reproductive medicine more 
of a business than a research enterprise.57
Exacerbating matters further is the fact that ARTs are 
often not covered by insurance.
 Further, dissociation 
from research serves the needs of those invested—both fiscally 
and professionally—in reproductive medicine. The market is 
based in large part on the therapeutic status of ARTs. Research 
questions will rest, in part, on questions about the safety and 
efficacy of interventions that are currently revenue-generating. 
Moreover, an absence of short-term and long-term data can be 
advantageous in a commercial environment in which economic 
returns are maximized by performing procedures. Among some 
commercially oriented health-care providers, there might be 
limited interest in developing data that could call into question 
the efficacy or safety of intervention or dramatic changes in 
practice. 
58
                                                          
 56. ANDREA L. BONNICKSEN, IN VITRO FERTILIZATION 82 (1989). 
 Restrictions on coverage are 
often based on the question of whether infertility should be 
considered an illness (despite the suffering it does clearly 
cause), and the claim that treatment is elective. The result is 
that any role insurance might play in encouraging evidence-
based practice is minimized in the context of ARTs. Data 
indicates that insurance coverage has an impact not only on 
how many individuals have access to treatment, but on how 
 57. See generally SPAR, supra note 9, at 195 (describing the baby making 
business as a growing business). 
 58. See Tarun Jain et al., Insurance Coverage and Outcomes of In Vitro 
Fertilization, 347 NEW ENG. J. MED. 661, 661 (2002) (stating that in the 
United States, in vitro fertilization is primarily a privately funded treatment). 
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fertility care is practiced. A landmark study in the New 
England Journal of Medicine, for example, found that state-
mandated insurance coverage is associated with what might be 
concluded as more evidence-based and safer treatment: lower 
numbers of embryos transferred per cycle and lower numbers of 
pregnancies with three or more fetuses.59
As a result of these social, clinical, political, and economic 
forces, reproductive medicine has come to occupy a space on the 
spectrum of research and therapy much closer to the latter, 
even at innovations’ early stages. But even in circumstances 
when all would agree to its status as a research endeavor, 
current approaches to oversight are unlikely to afford research 
participants and beneficiaries the protections they deserve. 
While a full treatment of regulatory oversight for research is 
beyond the scope of this paper, the major challenges and 
opportunities for oversight of innovation in ARTs are 
considered. 
 Limited insurance 
coverage contributes to the tendency for fertility care to operate 
more as a business than other areas of medicine, with market 
forces instead of regulatory oversight shaping the parameters 
of practice. 
B. REGULATION AND OVERSIGHT 
In stark contrast to the complex regulatory structure 
regarding the oversight of research with human subjects in 
many fields of medicine, research and clinical treatment of 
infertility has been virtually unregulated. Instead “the 
regulation that exists is basically the result of inadvertent 
coverage of other areas such as abortion or fetal research 
legislation.”60
Federal funding of research activities has been a major 
source of protection of human subjects in other fields of 
 An important factor in the promulgation of this 
regulatory void has of course been the aforementioned 
dissociation of innovation in reproductive medicine from 
experimentation. Further, though, four of the usual sources of 
regulatory control of innovation in medicine—federal funding of 
research activities, federal legislation, the FDA, and self-
regulation by the industry—mark a minimally regulated space 
for innovation in ARTs. 
                                                          
 59. Id. 
 60. Patricia A. King, Reproductive Technologies, in 1 BIOLAW: A LEGAL 
AND ETHICAL REPORTER ON MEDICINE, HEALTH CARE, AND BIOENGINEERING § 
7-3.5(d) (Childress et al. eds., 1986). 
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medicine. Researchers funded by the federal government are 
subject to the DHHS regulations.61 On the other hand, 
reluctance to fund research on embryos and fetuses in the 
United States has resulted in the loss of what is otherwise an 
important source of oversight for innovative practices in fields 
other than reproductive medicine.62
Again, the story is one of protection gone awry. On July 25, 
1975, The National Commission for the Protection of Human 
Subjects of Biomedical and Behavioral Research submitted 
conclusions and recommendations that formed the basis for 
regulations that the U.S. Department of Health, Education, 
and Welfare (DHEW) issued later that year in research 
involving fetuses, pregnant women, and embryos for human in 
vitro fertilization.
 
63 Known as Subpart B of 45 C.F.R. 46, the 
regulations aimed to create further protections for these 
particular individuals when subjected to federally funded 
research activities.64
As structured, the regulations have served not to protect 
these “vulnerable” populations, but rather to thrust the 
activities in which they have been involved out of the 
regulatory purview of the DHHS regulations. Research in IVF 
has never been eligible for federal funding. Subpart B created a 
de facto moratorium on federal funding of IVF until an “ethics 
advisory board” (EAB) could make recommendations to the 
Secretary of the DHEW regarding “the acceptability from an 




                                                          
 61. See 45 C.F.R. § 46.101–103 (2009). 
 It was not until September of 1978, stimulated by a 
 62. See RONALD M. GREEN, THE HUMAN EMBRYO RESEARCH DEBATES: 
BIOETHICS IN THE VORTEX OF CONTROVERSY 15 (2001); Arthur L. Caplan, 
Letters, Needed: A Modest Proposal, 37 HASTINGS CENTER REP., Nov. 2007, at 
4–11; The Inst. for Sci., Law, and Tech. Working Group, Ill. Inst. of Tech., ART 
into Science: Regulation of Fertility Techniques, 281 SCI. 651, 651–52 (1998). 
 63. THE NAT’L COMM’N FOR THE PROTECTION OF HUMAN SUBJECTS OF 
BIOMED. AND BEHAVIORAL RESEARCH, RESEARCH ON THE FETUS, REPORT AND 
RECOMMENDATIONS (1975), available at 
http://bioethics.georgetown.edu/pcbe/reports/past_commissions/research_fetus.
pdf. 
 64. 45 C.F.R. § 46.201–207 (2009). 
 65. See 45 C.F.R. § 46.207(b) (2009); see also ETHICS ADVISORY BD., DEPT. 
OF HEALTH, EDUC., AND WELFARE, REPORT AND CONCLUSIONS: HEW SUPPORT 
OF RESEARCH INVOLVING HUMAN IN VITRO FERTILIZATION AND EMBRYO 
TRANSFER 1 (1979), available at 
http://bioethics.georgetown.edu/pcbe/reports/past_commissions/HEW_IVF_rep
ort.pdf) [hereinafter EAB SUPPORT OF IN VITRO]. 
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funding request (already approved by a study section) from 
Pierre Soupart of Vanderbilt, that the Secretary directed the 
EAB to formulate recommendations for research involving 
IVF.66 Dr. Soupart’s goal had been to fertilize 450 eggs and 
study them to see whether the IVF process caused any 
chromosomal damage.67 In March 1979 the EAB submitted a 
report recommending approval for federal funding of research 
on the safety and efficacy of IVF and embryo transfer and the 
study of spare, untransferred embryos.68 However, no 
Secretary of DHEW or DHHS ever approved the 
recommendations, and DHEW Secretary Patricia Harris 
allowed the EAB charter to lapse in 1980 when its funding 
expired.69 Although many efforts were made in the 1980s to 
reinstate the EAB, no federal action was ever taken.70 In 1988, 
the Office of Technology Assessment reported that the effect of 
the moratorium on federal funding was “to eliminate the most 
direct line of authority by which the Federal Government can 
influence the development of both embryo research and 
infertility treatment so as to avoid unacceptable practices or 
inappropriate uses.” 71
The Revitalization Act of 1993 ended the de facto 
moratorium on research on IVF by nullifying the mandate that 
the EAB review any application or proposal for funding before 
its approval.
 
72 Subsequently, NIH director Harold Varmus 
established the Human Embryo Research Panel to determine 
which projects involving human embryos should be ethically 
acceptable for federal funding.73
                                                          
 66. EAB SUPPORT OF IN VITRO, supra note 
 Among the most controversial 
aspects of the report was the recommendation that it might be 
ethical to fund research projects in which human embryos are 
created solely for research purposes. Before the NIH could 
65, at 1. 
 67. See Anne Taylor Fleming, New Frontiers in Conception: Medical 
Breakthroughs and Moral Dilemmas, N.Y. TIMES, Jul. 20, 1980, at 48. 
 68. See ETHICS ADVISORY BD., US DEP’T OF HEALTH, EDUC., & WELFARE, 
REPORT AND CONCLUSIONS: HEW SUPPORT OF RESEARCH INVOLVING HUMAN 
IN VITRO FERTILIZATION AND EMBRYO TRANSFER 104 (1979) 
 69. Joseph Palca, Capital Report: A Word to the Wise, 24 HASTINGS 
CENTER REP., Mar.–Apr. 1994, at 5 (1994). 
 70. See Fletcher, supra note 53, at E-11. 
 71. OFF. OF TECHNOLOGY ASSESSMENT, U.S. CONG., INFERTILITY: 
MEDICAL AND SOCIAL CHOICES 179 (1988), available at 
http://www.fas.org/ota/reports/8822.pdf. 
 72. National Institutes of Health Revitalization Act of 1993, Pub. L. No. 
103-43, 113. 
 73. See Meeting of Panel/Request for Public Comment, 59 Fed. Reg. 
28,874, 28,875 (June 3, 1994). 
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respond, President Clinton declared that federal funds should 
not be allocated for the creation of embryos for research 
purposes.74 Varmus subsequently decided to accept the Panel’s 
recommendations not proscribed by the President’s 
declaration,75 but again a window of opportunity was quickly 
shut. In 1996 and each year subsequently, Congress has 
attached a rider to the DHHS appropriations bill (the Dickey-
Wicker Amendment), stating that no funds could be 
appropriated for any project involving “1) the creation of a 
human embryo or embryos for research purposes; or 2) research 
in which a human embryo or embryos are destroyed, discarded 
or knowingly subjected to risk of injury or death greater than 
that allowed for research on fetuses in utero under 45 C.F.R. 
46.208(a)(2) and section 498(b) of the Public Health Service Act 
(42 USC 289g(b)).”76
Given federal funding restrictions, the curious evolution of 
ICSI begins to make more sense. Because scientifically rigorous 
development and refinement of ICSI would have involved the 
creation, destruction, and discarding of embryos, research 
involving this technique would not have been eligible for 
federal funding. As such, the technology advanced rapidly with 
neither federal funding, nor the scientific scrutiny or human 
subjects’ protections that accompany it. 
 Thus the assisted reproductive 
technologies have progressed without federal funding, and the 
human subjects participating in these innovative technologies 
have not been protected by federal regulations that apply to 
other fields of medicine. 
Some of the industry’s leaders have argued, conversely, 
that the fertility industry is highly regulated,77 and point to 
three sources of regulation in particular. First, they cite 
existing legislation, including voluntary reporting requirements 
for outcomes of fertility treatment. In 1992, the Fertility Clinic 
Success Rate and Prevention Act78
                                                          
 74. Statement of Federal Funding of Research on Human Embryos, 30 
WEEKLY COMP. PRES. DOC. 2459 (Dec. 2, 1994). 
 set forth a requirement that 
 75. J.C. Fletcher, Ethics and Society: U.S. Public Policy on Embryo 
Research: Two Steps Forward, One Large Step Back, 10 HUMAN 
REPRODUCTION 1875, 1875 (1995). 
 76. 1 NAT’L BIOETHICS ADVISORY COMM’N, ETHICAL ISSUES IN HUMAN 
STEM CELL RESEARCH 35 (1999). 
 77. Robert W. Rebar & Alan H. DeCherney, Assisted Reproductive 
Technology in the United States, 350 NEW ENG. J. MED. 1603, 1604 (2004). 
 78. See 42 U.S.C. § 263a-1 (2006). 
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the CDC develop model standards for the state certification of 
embryo laboratories. It also required the CDC to publish 
pregnancy success rates for ART procedures carried out in 
fertility clinics in the United States.79 The first report was 
issued in December of 1997 and was based on data from 1995.80
Next, industry leaders cite the reach of the FDA as a 
source of regulation. For one, ART laboratories, which handle 
human tissues, are subject to inspection. But also, the agency’s 
role in regulating use of innovative techniques has evolved, in 
particular in response to a technique known as ooplasm 
transfer, in which the ooplasm from a woman’s egg is injected 
into the ooplasm of another woman whose embryos previously 
failed to develop. Fetuses conceived with this technique were 
found to have Turner syndrome, a relatively rare sex 
chromosome abnormality, raising familiar worries about the 
rapid integration of techniques into practice without adequate 
preliminary work.
 
While an improvement over the regulatory void, the legislation 
is limited with regard to the question of research regulation. 
Participation in the program is voluntary without penalty to 
clinics for failure to report. More to the point, the publication of 
success rates is directed more at infertile patients as consumers 
than as subjects of research. It serves to catalog the practices 
and pregnancy rates of the majority of centers in the United 
States; patients can compare and contrast centers to help 
decide where to gamble substantial financial and emotional 
resources in their pursuit of pregnancy and childbearing. 
Guidelines for the introduction of new methods, informed 
consent and follow-up of long-term data are not addressed in 
the 1992 legislation. 
81 The FDA “notified researchers that it 
would require an IND” before the technique could be used 
again in humans, which essentially “amounted to a clinical 
hold” on the procedure.82
And finally, industry leaders cite professional guidelines, 
and the usefulness of self-regulation. In 1986, the president of 
 The story of ooplasm transfer, 
however, is a rare case of discretionary judgment by the FDA in 
a field it has tended to regard as beyond its purview. 
                                                          
 79. Id. 
 80. See Isabella A. Danel et al., 1995 Assisted Reproductive Technology 
Success Rates: National Summary and Fertility Clinic Report, 7 J. WOMEN’S 
HEALTH 301, 301 (1998). 
 81. Susan M. Hawes et al., Ooplasmic Donation in Humans: The Potential 
for Epigenic Modifications, 17 HUM. REPROD. 850, 851 (2002). 
 82. Bonnicksen, supra note 51, at 75. 
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the American Fertility Society (now the American Society for 
Reproductive Medicine, ASRM) first appointed an Ethics 
Committee, representing professionals in law, bioethics, and 
reproductive medicine.83 The committee has considered, on an 
ongoing basis, ethical issues which arise in the care of 
individuals with infertility. While the reports address 
important and clinically relevant issues, they fall short of 
providing adequate oversight for the protection of participants 
in innovative procedures. First of all, following the guidelines is 
voluntary, as adherence to the guidelines is not required for 
professional certification.84 Second, the guidelines have tended 
to be “more descriptive of current practice than normative”85 
though some recent reports are directive.86
The U.S. approach to regulation of innovative technologies 
stands in contrast to that of many other countries that regulate 
the movement of innovative technologies from laboratory to 
clinic.
 Third, the 
guidelines are directed toward the infertility profession and do 
not have input from the public nor from disciplines outside of 
law, medicine, and bioethics, and so even if enforceable, these 
guidelines would not incorporate the comprehensive input 
which these pressing social issues deserve. 
87
                                                          
 83. See, e.g., Stuart F. Spicker, Overview of the Reports of the Ethics 
Committee of the American Fertility Society, 14 J. MED. & PHIL. 477, 477 
(1989) (“In September 1986, the Ethics Committee of The American Fertility 
Society (AFS) issued its initial report.”). 
 While a comprehensive survey of other nations’ policies 
is outside the scope of this manuscript, a brief review places the 
U.S. approach in context. Since 1998, the International 
Federation of Fertility Societies (IFFS) has surveyed a growing 
number of principal sovereign nations across the world about 
 84. American Society for Reproductive Medicine, Practice Guidelines, 
http://www.asrm.org/Guidelines_for_Practice/ (last visited Apr. 22, 2010) 
(“These guidelines have been developed to assist physicians with clinical 
decisions regarding the care of their patients. They are not intended to be a 
protocol to be applied in all situations. . . . [A] [g]uideline presents a 
recommended approach to evaluation or treatment but is not intended to 
describe the only approved standard of practice or to dictate an exclusive 
course of treatment.”) 
 85. Cohen, supra note 52. 
 86. See, e.g., Ethics Comm. of the Am. Soc’y of Reprod. Med., Donating 
Spare Embryos for Stem Cell Research, 91 FERTILITY AND STERILITY 667, 667–
70 (2009). 
 87. Lori P. Knowles, The Governance of Reproductive Technology: 
International Models, in REPROGENETICS: LAW, POLICY, AND ETHICAL ISSUES 
127 (Lori P. Knowles & Gregory E. Kaebnick eds., 2007). 
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surveillance and oversight of ARTs.88 According to the 2007 
report, twenty-nine of fifty-seven nations surveyed have 
legislation regarding ARTs. The United States was one of 
seventeen to have guidelines; eleven countries reported neither 
statutory regulations nor voluntary guidelines.89 The authors of 
the report noted that laws and guidelines of all countries were 
markedly divergent and that only three countries consider the 
regulatory situation to be “satisfactory.”90
Among those is Great Britain, whose Human Fertilisation 
and Embryo Authority (HFEA) is often considered exemplary, 
though commentators often raise concern about how such an 
Authority would function in the U.S. political context.
 
91 The 
HFEA was established in August of 1991 by the Human 
Fertilisation and Embryology Act. The recommendation came 
from a 1984 report of the Committee of Inquiry into Human 
Fertilisation and Embryology (called the “Warnock” report).92 
In order to protect society “from its real and proper fear of a 
rudderless voyage into unknown and threatening seas,”93 the 
Warnock report recommended a statutory licensing authority 
to regulate the research and practice of new reproductive 
technologies.94 Among the HFEA’s many functions are 
licensure and monitoring of clinics that carry out IVF, donor 
insemination (DI), and human embryo research.95 Every clinic 
in the UK which carries out these activities is required by law 
to be licensed by the HFEA.96 The HFEA also has a data 
register containing details of the outcomes of licensed 
treatments and patient characteristics in the UK.97
                                                          
 88. Howard W. Jones, Jean Cohen, Ian Cooke, and Roger Kempers, IFFS 
Surveillance 2007, 87 FERTILITY & STERILITY S1, S1–67 (2007). 
 
Importantly, in addition to pregnancy rates (which are 
 89. Id. 
 90. Id. at S8. 
 91. John Robertson, The Virtues of Muddling Through, 37 HASTINGS 
CENTER REP., JULY–AUG. 2007, 26–28. 
 92. MARY WARNOCK, A QUESTION OF LIFE: THE WARNOCK REPORT ON 
HUMAN FERTILISATION AND EMBRYOLOGY (1985); HUMAN FERTILISATION & 
EMBRYOLOGY AUTHORITY, ABOUT THE HUMAN FERTILISATION & EMBRYOLOGY 
AUTHORITY 2 (2009), available at 
http://www.hfea.gov.uk/docs/About_the_HFEA.pdf [hereinafter ABOUT HEFA]. 
 93. Id. at 100. 
 94. Id. at 74. 
 95. See Human Fertilisation & Embryology Authority, Who We Are & 
What We Do, Our Role as Regulator, http://www.hfea.gov.uk/135.html (last 
visited Apr. 18, 2010). 
 96. ABOUT HEFA, supra note 92, at 3–6. 
 97. Id. at 8, 15. 
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catalogued on a voluntary basis in the US), the HFEA collects 
data about developmental defects and syndromes that result 
from these procedures.98 The HFEA also regulates research 
involving human embryos, and no new technique can be 
applied in humans without the approval of the HFEA.99
Harvard law professor Elizabeth Bartholet contrasts the 
activities of other countries with the situation in the United 
States: “This country is the only country in our technological 
position that hasn’t, as a society, faced up to the various social 
and ethical issues involved in this technology.”
 
100 Individuals in 
other countries have recognized the permissive approach in the 
United States; some have in fact have seized on the lack of 
regulations here as a means to overcome barriers they have 
faced in their own countries to ethically concerning 
technologies.101
III. ETHICAL AND POLICY ISSUES 
 Reports have highlighted the United States as 
a “trade center” for reproductive and genetic technologies, 
drawing customers whose own countries ban given procedures. 
In contrast to the problematic efflux of ethically questionable 
research in other areas of medicine, the United States is seen 
among foreigners as a land of opportunity for the clinical 
application of novel reproductive procedures of unproven safety 
and unexamined societal import. 
As a result of the clinical and (lacking) regulatory structure 
in the United States upon which innovation in reproductive 
medicine is undertaken, several ethical and policy issues have 
surfaced. As intimated throughout the discussion thus far, new 
reproductive technologies raise at least three problems: 1) rapid 
introduction and integration of new technologies into clinical 
practice without a systematic way to insure that innovative 
therapies are reviewed prior to clinical application, 2) 
inadequate informed consent, and 3) lack of uniform standards 
for collection of data and surveillance of outcomes. The 
                                                          
 98. HUMAN FERTILISATION & EMBRYOLOGY AUTHORITY, HUMAN 
RESEARCH IN THE UK 3–8 (2006/2007), available at 
http://www.hfea.gov.uk/docs/HFEA_Human-Embryo-Research-06-07.pdf. 
 99. Id. at 6. 
 100. ANDREWS, supra note 2, at 221. 
 101. See, e.g., Alice Fishburn. U.S. Clinic Offers British Couple the Chance 
to Choose the Sex of Their Child, TIMES ONLINE, August 22, 2009, 
http://www.timesonline.co.uk/tol/life_and_style/health/article6805880.ece (last 
visited May 6, 2010). 
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acceleration of science has made the laissez-faire approach to 
progress in reproductive medicine a subject of even greater 
urgency than it had been in previous years, when other 
innovative techniques set the stage of a similar debate. This 
mounting urgency becomes clear upon further consideration of 
the three problems which tend to characterize innovation in 
reproductive medicine. 
A. PREMATURE INTEGRATION INTO PRACTICE 
The first problem associated with reproductive medicine is 
that innovation is often characterized by rapid integration of 
new technologies into clinical practice without scientifically 
rigorous safety or efficacy data. Lori Andrews quoted one 
infertility doctor as saying: “We go from mindside to bedside in 
two weeks.”102 As discussed in the introduction, ICSI became 
standard practice in the vast majority of U.S. infertility clinics 
over the course of less than ten years. After only one year of 
clinical experience in the U.S. and in the absence of any long 
term data, the Practice Committee of the American Society for 
Reproductive Medicine recognized ICSI as clinical practice, 
stating “[s]everal recent independent studies have 
demonstrated the efficacy and short term safety of ICSI. Thus, 
its use for the treatment of male factor infertility is no longer 
considered experimental.”103
B. INFORMED CONSENT 
 The procedure is now promoted, 
billed, and treated as standard therapy despite the fact that 
safety data is just now emerging. There is no regulatory 
framework which requires evidence of basic scientific merit, 
clinical benefit, or a favorable risk/benefit ratio before these 
new techniques can be integrated in to clinical practice. 
The second problem concerns the adequacy of informed 
consent. In a 1996 resolution, a joint council of the American 
Medical Association (AMA) issued a statement that informed 
consent to ARTs is often inadequate and inasmuch as it is, 
“subtle deception.”104
                                                          
 102. Lori B. Andrews, We Need Regulation of Reproduction, in CLONING: 
FOR AND AGAINST 180 (M. L. Rantala & Arthur J. Milgram eds. 1999). 
 Similarly, the New York State Task Force 
 103. AM. SOC’Y FOR REPRODUCTIVE MED., PRACTICE COMMITTEE 
STATEMENT 2 (1994). 
 104. AM. MED. ASS’N COUNCIL ON ETHICAL & JUD. AFF. & COUNCIL ON SCI. 
AFF., ISSUES OF ETHICAL CONDUCT IN ASSISTED REPRODUCTIVE TECHNOLOGY 
2 (1996), available at http://www.ama-
assn.org/ama1/pub/upload/mm/369/70b.pdf. 
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on Life and the Law studied the medical literature, consent 
forms used by practitioners in New York State, and interviewed 
patients and practitioners, and concluded, “There is 
considerable evidence that physicians provide incomplete or 
misleading information about benefits and risks, particularly 
the risks associated with multiple gestation,” and that “New 
York should enact legislation establishing minimum standards 
for obtaining informed consent to ARTs.”105
The context of reproductive medicine certainly exacerbates 
challenges to informed consent. Intense media attention, 
hopeful couples, and optimism on the part of physicians all 
create challenges to the adequacy of even the most carefully 
worded and exhaustive informed consent process. Furthermore, 
the commercial backdrop of ARTs may incline some providers 
to minimize risks and encourage treatment given financial 
incentives to treat. Given this enthusiasm, it can be unclear to 
participants just how experimental particular techniques are, 
or—given positive connotations of innovation—what the risks 
of innovative therapeutics might be. 
 
But even when risks are known and communicated, 
patients hoping for a baby may discount the risks due to 
hopefulness, magical thinking, or cognitive challenges known to 
limit our ability to predict future emotional states.106 Indeed, 
patients have described, in retrospect, the difficulty they 
encountered imagining how they would dispose of spare frozen 
embryos in advance of fertility treatment, reflecting the 
challenges of projecting future preferences.107 Furthermore, 
fertility patients’ decisions about treatment may also simply be 
more strongly influenced by the potential for treatment success 
(i.e., a ‘take home baby’) than by risks to themselves or to 
future offspring.108
                                                          
 105. TASK FORCE ON LIFE & THE LAW, N.Y. STATE, EXECUTIVE SUMMARY 
OF THE TASK FORCE ON LIFE AND THE LAW, 
http://www.health.state.ny.us/nysdoh/taskfce/execsum.htm (last visited Apr. 
22, 2010). 
 In other words, they may find real risks to 
 106. See generally Jodi Halpern & Robert M. Arnold, Affective Forecasting: 
An Unrecognized Challenge in Making Serious Health Decisions, 23 J. GEN. 
INTERNAL MED. 1708 (2008) (discussing “affective forecasting” and its 
implications for those facing health decisions). 
 107. Anne Drapkin Lyerly et al., Fertility Patients’ Views About Frozen 
Embryo Disposition: Results of a Multi-Institutional U.S. Survey, 93 FERTILITY 
& STERILITY 499, 502 (2010). 
 108. G. S. Scotland et al., Safety Versus Success in Elective Single Embryo 
Transfer: Women’s Preferences for Outcomes of In Vitro Fertilisation, 114 
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themselves and their babies as acceptable given the alternative 
of having no baby at all. And finally, the lack of information 
about outcomes of new techniques means patients have a 
limited basis upon which to decide whether to engage in the 
procedures, calling into question the validity of consent to 
participate in novel ARTs. 
C. SURVEILLANCE 
The third problem associated with current approaches to 
innovation in reproductive medicine is the lack of uniform 
standards for collection of data and surveillance of outcomes. 
While the CDC registry reports pregnancy rates at 
participating infertility centers, there is no coordinated registry 
which reports any health outcomes in children or women 
exposed to new reproductive technologies in the United States. 
The data regarding outcomes of children conceived by ICSI 
were collected in Belgium and Australia109—ICSI children in 
the United States are not followed. Similarly, questions about 
links between fertility treatment and breast and ovarian cancer 
as well as concerns about long term cardiovascular risk in 
women who have conceived with ARTs have both emerged from 
retrospective data rather than carefully crafted surveillance. 
The failure to follow women prospectively has resulted in at 
best incomplete and potentially misleading information for 
patients considering ARTs. Furthermore, long term outcomes of 
these procedures, such as the reproductive health of children 
created by assisted conception are only just becoming 
measurable. In 1999, Louse Brown’s sister Natalie became the 
first “test-tube baby” to bear a child on her own.110
IV.  MOVING FORWARD 
 
These three ethical challenges—rapid introduction of new 
procedures without adequate evidence of safety or efficacy, 
inadequate informed consent, and lack of uniform standards for 
surveillance of outcomes—present a set of issues of critical 
                                                          
BRITISH J. OBSTETRICS & GYNAECOLOGY 977, 978 (2007). 
 109. A. Van Steirteghem et al., Follow-up of Children Born After ICSI, 8 
HUMAN REPRODUCTION UPDATE 111 (2002); Michèle Hansen et al., The Risk of 
Major Birth Defects after Intracytoplasmic Sperm Injection and in Vitro 
Fertilization, 346 NEW ENG. J. MED. 725 (2002); see also Genetic Concerns over 
Fertility Treatments, BBC NEWS, Dec. 15, 1998, 
http://news.bbc.co.uk/2/hi/health/235419.stm (last visited Apr. 18, 2010). 
 110. Carey Goldberg, Just Another Girl, Unlike Any Other, N.Y. TIMES, 
Oct. 27, 1999, at A16. 
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importance to the public and suggest a pressing need for a 
better approach. The decentralized and incremental policy 
around regulation of assisted reproductive policies will 
continue to generate inquiries and inspire debate. The correct 
policy for regulation—of practice and of innovation—has yet to 
be agreed upon. But critically, moving forward policymakers 
should attend to the morally and scientifically important 
distinctions between research and practice. The failure to do so 
in the past—on the part of physicians, scholars and 
policymakers alike—has had serious consequences. The 
challenges of regulating innovation in ARTs are distinct from 
those of regulating the practice of ART and need their own 
solutions. Fortunately, some initial approaches to remedying 
problems emerging from the lack of oversight are potentially 
straightforward. 
First, funding is needed for research on ARTs—both 
because it will generate more information needed for the 
informed consent process and because it opens the door to 
regulation by the funding organization. After a decade of 
advocacy by scientists and health groups, access to federal 
funding for research on stem cell lines has recently become 
available (and regulations for such research developed). Yet 
funds for research on IVF techniques (which cross many of the 
same moral chasms) has not materialized, due in part to the 
ongoing force of the Dickey-Wicker Amendment.111 Efforts to 
restrict funding for research have meant that innovation has 
occurred in a clinical setting without the requirements for 
informed consent or oversight usually afforded to research. 
According to the authors of the 2008 Cochrane review of 
evidence about the effectiveness of ARTs, “despite the large 
emotional and economic burden resulting from infertility, there 
is relatively little high-quality evidence to support the choice of 
specific interventions. Removing barriers to conducting 
appropriately designed studies should be a major policy 
goal.”112
Second, data is needed on health implications of ARTs for 
women and children. One approach would be to expand 
requirements for reporting to include more detailed 
information about pregnancy outcomes and longer term health 
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outcomes for both children and the women who undergo ARTs. 
Clearly this would present challenges since the fertility clinics 
that report to the CDC are not likely to routinely collect 
detailed information about obstetrical or long term outcomes, 
as patients are generally transferred to obstetricians once 
pregnancy is established. The challenges are clearly not 
insurmountable, as small strides toward collecting more 
complete pregnancy outcome data have been made. For 
instance, the CDC recently added a requirement to report 
singleton live births as a separate measure, since multiple 
gestations have a higher risk profile (for women and children 
both) compared to singleton births.113 There may be other 
approaches to collecting these data as well, particularly 
observational studies of women and children during and after 
pregnancy. Coauthors and I have argued elsewhere that the 
U.S. National Children’s Study, which plans to enroll 100,000 
women prior to or in the first trimester of pregnancy and follow 
them and their children for 21 years has the potential to be a 
valuable source of information on the impact of IVF, 
particularly if maternal outcomes of pregnancy are added.114
Third, requirements for informed consent should be both 
clarified and standardized. They should include guidance about 
the distinct differential requirements for consent to 
participating in research versus consent to participating in 
clinical practice that necessarily includes inadequately tested 
though standard procedures. The practice committees of the 
American Society for Reproductive Medicine (ASRM) and the 
Society for Assisted Reproductive Technology have made 
important progress, but because they identify “elements to be 




 the guidelines are neither 
enforceable nor uniformly followed.  While progress has been 
made in describing requirements for informed consent for 
human oocyte, embryo, and embryonic stem cell research aimed 
specifically at stem cell transplantation for degenerative 
diseases (in other words, non-reproductive use of gametic or 
embryonic tissue),116
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requirements for informed consent for the therapeutic 
advancement of fertility that may likewise involve embryo 
manipulation or destruction. 
Finally, while it is critical to mark the dividing line 
between innovation and practice in conversations about ethics 
and policy, there is a different dividing line whose blurring or 
erasure may to prove beneficial. In contrast to those who argue 
that the scope of conversation about regulation should be 
limited to research on embryos and fetuses that are outside a 
woman’s body,117
This point is not specific to practice: ethics and policy 
discussions about the regulation of innovation would benefit 
from a more unified approach that does not limit its purview to 
pre-gestation events. Section III.A highlights several 
challenges that have drawn both ARTs and maternal-fetal care 
outside the umbrella of research oversight and led to a paucity 
of safety and efficacy data: protectionist policies, tendencies to 
overlook the gestating or potentially gestating woman, 
regulatory loopholes specific to procedures, presumed 
therapeutic status associated with birth, and high consumer 
demand, to name a few. Given their shared genesis, the 
problems of innovation in pre- and post-conception reproductive 
 it can be argued the distinction complicates 
and potentially distorts ethical and policy analyses, and that 
more progress might be made with a more inclusive approach 
that encompasses reproductive care across prior to and 
following conception. The division of both clinical and moral 
labor (between fertility care and maternal-fetal medicine) can 
obscure or even worsen the situation when ethical questions 
regarding innovation are under consideration. For instance, at 
the clinical level, a longstanding disconnect between the goals 
of fertility care (pregnancy) and the goals of obstetrical care 
(singleton birth) has likely contributed to the high rates of 
multiple gestation. An important corrective has been reporting 
data about rates of singleton births (traditionally considered 
obstetrical data) in the CDC Fertility Clinic reports. Clearly, 
discontinuities in the care of patients and in conceptions of 
reproductive “success” in the application of new reproductive 
technologies have exacerbated the ethical and regulatory 
challenges in practice. 
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medicine are likely to have shared solutions. Finally, as we 
develop better understandings of epigenetics—of how 
environmental, nutritional and other factors before and during 
pregnancy can affect an offspring’s health—recognition of the 
continuity of conception, gestation, birth, and long term health 
for women and children will be critical to coherent policy. 
V. CONCLUSIONS 
The evolution of technology in reproductive medicine raises 
questions that are critical to patients and families today and 
which have profound implications for future generations. On 
the one hand, new techniques may provide relief of the 
suffering caused by infertility and the birth of children with 
preventable disabilities. On the other hand, innovation has 
ushered in problems with its progress. At the heart of the issue 
is their development in a social, clinical, political, and economic 
context that has distanced “innovation” from 
“experimentation.” The blurring of boundaries has resulted in a 
failure of oversight of human subjects research in reproductive 
medicine in the United States, and in the unwitting 
participation of thousands of individuals in experimental 
procedures without the protection of appropriately careful 
clinical investigation, informed consent, or data collection and 
reporting of outcomes. Though rich literature has recently 
developed about the merits and pitfalls of regulation for the 
practice of ARTs, much less discussion of late has focused on 
the process that has brought these ARTs to the bedside, despite 
the implications of unregulated innovation for the health of 
women and children. Better oversight of innovation in 
reproductive medicine is likely to result in safer technologies, 
better outcomes, and more informed decisions by men and 
women in the process of fertility care. 
 
